Filing Details

Accession Number:
0001104659-14-075070
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-10-30 08:23:41
Reporting Period:
2014-10-27
Filing Date:
2014-10-30
Accepted Time:
2014-10-30 08:23:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1359931 Proteon Therapeutics Inc PRTO Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1133921 Helmut Schuhsler C/O Tvm Capital Group
Ottostrasse 4
Munich 2M 80333
No No Yes No
1318584 Tvm Life Science Ventures Vi Lp C/O Tvm Capital Group
Ottostrasse 4
Munich 2M 80333
No No Yes No
1397372 Alexandra Goll C/O Tvm Capital Group
Ottostrasse 4
Munich 2M 80333
No No Yes No
1398596 Stefan Fischer C/O Tvm Capital Group
Ottostrasse 4
Munich 2M 80333
No No Yes No
1599744 Tvm Life Science Ventures Vi Gmbh & Co Kg C/O Tvm Capital Group
Ottostrasse 4
Munich 2M 80333
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-10-27 223,410 $10.00 223,410 No 4 P Direct
Common Stock Acquisiton 2014-10-27 76,590 $10.00 300,000 No 4 P Indirect By TVM Life Science Ventures VI, L.P.
Common Stock Acquisiton 2014-10-27 1,107,154 $0.00 1,407,154 No 4 C Direct
Common Stock Acquisiton 2014-10-27 379,462 $0.00 1,786,616 No 4 C Indirect By TVM Life Science Ventures VI, L.P.
Common Stock Acquisiton 2014-10-27 116,511 $4.60 1,903,127 No 4 X Direct
Common Stock Acquisiton 2014-10-27 39,932 $4.60 1,943,059 No 4 X Indirect By TVM Life Science Ventures VI, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Indirect By TVM Life Science Ventures VI, L.P.
No 4 C Direct
No 4 C Indirect By TVM Life Science Ventures VI, L.P.
No 4 X Direct
No 4 X Indirect By TVM Life Science Ventures VI, L.P.
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Convertible Preferred Stock Disposition 2014-10-27 4,468,482 $0.00 335,680 $0.00
Common Stock Series A Convertible Preferred Stock Disposition 2014-10-27 1,531,518 $0.00 115,051 $0.00
Common Stock Series A-1 Convertible Preferred Stock Disposition 2014-10-27 2,092,735 $0.00 160,779 $0.00
Common Stock Series A-1 Convertible Preferred Stock Disposition 2014-10-27 717,260 $0.00 55,105 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2014-10-27 2,436,618 $0.00 189,063 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2014-10-27 835,121 $0.00 64,799 $0.00
Common Stock Series C Convertible Preferred Stock Disposition 2014-10-27 2,331,391 $0.00 180,898 $0.00
Common Stock Series C Convertible Preferred Stock Disposition 2014-10-27 799,043 $0.00 61,999 $0.00
Common Stock Series D Convertible Preferred Stock Disposition 2014-10-27 3,727,823 $0.00 234,897 $0.00
Common Stock Series D Convertible Preferred Stock Disposition 2014-10-27 1,277,663 $0.00 80,508 $0.00
Common Stock Warrants (Right to Buy) Disposition 2014-10-27 116,511 $0.00 116,511 $4.60
Common Stock Warrants (Right to Buy) Disposition 2014-10-27 39,932 $0.00 39,932 $4.60
Series D Convertible Preferred Stock Option (Right to Purchase) Disposition 2014-10-27 1,316,683 $0.00 82,966 $0.00
Series D Convertible Preferred Stock Option (Right to Purchase) Disposition 2014-10-27 451,276 $0.00 28,455 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Indirect
0 No 4 C Direct
0 No 4 C Indirect
0 No 4 C Direct
0 No 4 C Indirect
0 No 4 C Direct
0 No 4 C Indirect
0 No 4 C Direct
0 No 4 C Indirect
0 No 4 X Direct
0 No 4 X Indirect
0 No 4 J Direct
0 No 4 J Indirect
Footnotes
  1. These shares were purchased in connection with the Issuer's initial public offering of Common Stock.
  2. The shares are directly held by TVM Life Science Ventures VI GMBH & Co. KG ("TVM VI"). Hubert Birner ("Birner"), Alexandra Goll ("Goll"), Helmut Schuhsler ("Schuhsler") and Stefan Fischer ("Fischer") are members of the investment committee of TVM Life Science Ventures Management VI L.P. ("TVM VI Management"), a special limited partner of TVM VI, with voting and dispositive power over the shares held by TVM VI. Fischer, Goll and Schuhsler each disclaim beneficial ownership of the shares held by TVM VI, except to the extent of any pecuniary interest therein, if any.
  3. The shares are directly held by TVM Life Science Ventures VI L.P. ("TVM VI LP"). Birner, Goll, Schuhsler, Fischer and Polack are members of the investment committee of TVM VI Management, a special limited partner of TVM VI LP, with voting and dispositive power over the shares held by TVM VI LP. TVM VI Management, Fischer, Goll and Schuhsler each disclaim beneficial ownership of the shares held by TVM VI LP, except to the extent of any pecuniary interest therein, if any.
  4. Upon the closing of the Issuer's initial public offering, each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1-for-1.19 basis without payment of further consideration and with no expiration date.
  5. Reflects a 1-for-15.87 reverse stock split effected on October 6, 2014.
  6. Upon the closing of the Issuer's initial public offering, each share of Series A-1 Convertible Preferred Stock automatically converted into Common Stock on a 1-for-1.22 basis without payment of further consideration and has no expiration date.
  7. Upon the closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1-for-1.23 basis without payment of further consideration and has no expiration date.
  8. Upon the closing of the Issuer's initial public offering, each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1-for-1.23 basis without payment of further consideration and has no expiration date.
  9. Upon the closing of the Issuer's initial public offering, each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a one-for-one basis (without payment of further consideration and with no expiration date) plus an additional 5,837 incremental shares as a result of an adjustment as provided for in the Company's certificate of incorporation.
  10. Upon the closing of the Issuer's initial public offering, each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a one-for-one basis (without payment of further consideration and with no expiration date) plus an additional 2,000 incremental shares as a result of an adjustment as provided for in the Company's certificate of incorporation.
  11. Upon the closing the Issuer's initial public offering, TVM VI exercised their warrants with cash to purchase common stock.
  12. Upon the closing the Issuer's initial public offering, TVM VI LP exercised their warrants with cash to purchase common stock.
  13. TVM VI had a right to purchase shares of Series D Convertible Preferred Stock under the Series D Purchase Agreement at a price of $0.588656, which right to purchase ceased to be exercisable upon the initial filing of the Issuer's registration statement for its initial public offering, and terminated upon the completion of the Issuer's initial public offering of Common Stock. Each share of Series D Preferred Stock issuable upon exercise of the right to purchase would have been convertible into shares of the Issuer's common stock as described in footnote (9) above.
  14. TVM VI LP had a right to purchase shares of Series D Convertible Preferred Stock under the Series D Purchase Agreement at a price of $0.588656, which right to purchase ceased to be exercisable upon the initial filing of the Issuer's registration statement for its initial public offering, and terminated upon the completion of the Issuer's initial public offering of Common Stock. Each share of Series D Preferred Stock issuable upon exercise of the right to purchase would have been convertible into shares of the Issuer's common stock as described in footnote (10) above.